Home About Chat Users Issues Party Candidates Polling Firms Media News Polls Calendar Key Races United States President Senate House Governors International

New User Account
"A comprehensive, collaborative elections resource." 
Email: Password:

  As opioid deaths rise, pharma firm hikes price of antidote more than six-fold
NEWS DETAILS
Parent(s) Issue 
ContributorRP 
Last EditedRP  Feb 01, 2017 01:10pm
Logged 0
CategoryGeneral
AuthorShefali Luthra
MediaNewspaper - Philadelphia Inquirer
News DateMonday, January 30, 2017 03:35:00 PM UTC0:0
DescriptionFirst came Martin Shkreli, the brash young pharmaceutical entrepreneur who raised the price for an AIDS treatment by 5,000 percent. Then, Heather Bresch, the CEO of Mylan, who oversaw the price hike for its signature Epi-Pen to more than $600 for a twin-pack, though its active ingredient costs pennies by comparison.

Now a small Virginia company called Kaleo is joining their ranks. It makes an injector device that is suddenly in demand because of the nation’s epidemic use of opioids, a class of drugs that includes heavy painkillers and heroin.

And as demand for Kaleo’s product has grown, the privately held firm has raised its twin-pack price to $4,500, from $690 in 2014.
Share
ArticleRead Full Article

NEWS
Date Category Headline Article Contributor

DISCUSSION